CN114601766A - A skin lipid mixed liposome containing cationic substances and skin-caring product prepared from the same - Google Patents
A skin lipid mixed liposome containing cationic substances and skin-caring product prepared from the same Download PDFInfo
- Publication number
- CN114601766A CN114601766A CN202210223465.8A CN202210223465A CN114601766A CN 114601766 A CN114601766 A CN 114601766A CN 202210223465 A CN202210223465 A CN 202210223465A CN 114601766 A CN114601766 A CN 114601766A
- Authority
- CN
- China
- Prior art keywords
- hydrosol
- cationic
- skin
- hydrolat
- liposome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/361—Carboxylic acids having more than seven carbon atoms in an unbroken chain; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/68—Sphingolipids, e.g. ceramides, cerebrosides, gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/54—Polymers characterized by specific structures/properties
- A61K2800/542—Polymers characterized by specific structures/properties characterized by the charge
- A61K2800/5426—Polymers characterized by specific structures/properties characterized by the charge cationic
Abstract
The invention relates to a hydrolat skin-imitated lipid mixed liposome containing cationic substances and a skin-beautifying product prepared from the same. The invention belongs to the field of cosmetics. Specifically, the invention relates to a hydrolat skin-imitated lipid mixed liposome containing cationic substances, a preparation method thereof and a skin-beautifying product prepared from the liposome.
Description
Technical Field
The invention belongs to the technical field of cosmetics. Specifically, the invention relates to a hydrolat skin-imitated lipid mixed liposome containing cationic substances and a preparation method thereof, and also relates to a skin-beautifying product prepared from the skin-imitated lipid mixed liposome.
Background
Since the discovery of liposomes in 1964, 57 years have been known. The liposome is a closed vesicle formed by dispersing lipid such as phospholipid with a similar biological membrane structure in water, the thickness of the membrane wall is about 5-7 nm, and the diameter of the vesicle is generally different from 25-500 nm. In 1976 Gregoriadis et al, in view of the characteristics of special structure of liposome, good biocompatibility of phospholipid and the like, the liposome is used as a carrier to wrap the drug, and the results show that the distribution of the drug-loaded liposome in vivo is different from that of a pure drug, the half-life period in blood circulation is prolonged, the toxic and side effects of the drug are obviously improved, and the solubility of the drug is changed. After years of research, many liposome pharmaceutical preparations are continuously approved to be marketed, such as amphotericin B liposome (AmBisome), doxorubicin liposome (Doxil, Caelyx, Myocet), daunorubicin liposome (Daunoxome), cytarabine liposome (Depocyt), and the like.
Due to the characteristics of liposome, researchers not only apply the liposome to the field of medicine, but also the application of the liposome to the field of cosmetics is started as early as 80 years in the 20 th century, and in 1986, the first liposome cosmetic named 'Capture' in the world is developed by Dior for Lantome company of France, and then the liposome cosmetic is gradually popularized in various countries.
Nowadays, liposome technology is still a new cosmetic research hotspot, and is more mature and reliable after years of development. Since the use of liposomes in cosmetics, the search for the effect of liposomes on skin has begun. The mechanism of action of liposomes is not well understood at present, but there are generally two main theories: (1) after the liposomes are applied to the skin, the lipid bilayer membrane is ruptured to form a closed membrane on the skin, and then the active ingredient permeates into the epidermis while the lipid remains on the skin. (2) Since the main component constituting the liposome is phospholipid, which is also the main component of the cell, and the form thereof is similar to that of the cell, the liposome has strong affinity with the cell. The lipid bilayer membrane interacts with the biological membrane, and the active ingredients are released and absorbed; or the intact liposomes are phagocytosed by the cell and then resorbed into the cytoplasm.
Although liposomes have been used in the cosmetic field for many years, they have not become widespread, and only a few advanced skin care brands are currently on the market containing liposomes, such as: dior, Yashilan Dai, Lankan, Guangxi Lightenwick, etc.
The cationic substance is a positively charged substance, and the ionized hydrophilic group is a positively charged cation when the substance is dissolved in water, so that the cationic substance has stronger skin adhesion performance.
Hyaluronic acid is an acidic mucopolysaccharide, which was first isolated from bovine vitreous humor by Meyer et al, university of Columbia, 1934. The skin care cosmetic has unique skin protection effect, can keep skin moist, smooth, fine, tender and elastic, and has the effects of preventing wrinkles, resisting wrinkles, beautifying, protecting health and recovering physiological functions of the skin. However, hyaluronic acid is negatively charged because it contains a carboxyl functional group, and the surface of human skin and hair is also negatively charged, and unmodified hyaluronic acid is not easily adsorbed by human skin and hair because of negative charge, and thus a good moisturizing effect is not achieved.
The cationic hyaluronic acid is made by cationizing hyaluronic acid to make it electropositive, so that the cationized hyaluronic acid is easily adsorbed on the surface of skin or hair. Besides high moisture retention property and high viscoelasticity which are the same as those of hyaluronic acid, the hyaluronic acid gel also has good adsorbability and affinity, is applied to the surface of skin to keep the skin in a moist state, and is not easy to wash away by running water during washing. When the skin care product is applied to skin care products, the skin feel is fresh and cool without greasy feel, the ductility is good when the skin care product is applied, and the skin can become more moist and glossy after the skin care product is used, so that the skin color is brightened.
The hydrosol, also called water essential oil, is a condensed water solution obtained by distilling aromatic plants and fresh flowers, has natural and pure components, light and pleasant fragrance, and the characteristic of low concentration of the hydrosol is easily absorbed by skin, is mild and is not irritant. The hydrolat contains about 0.3% to 0.5% of the water-soluble components of the essential oil, so that the fragrance, partial curative effect and slight antibacterial property of the essential oil are still maintained.
At present, common hydrolat mainly comprises rose hydrolat, tea hydrolat, lavender hydrolat, jasmine hydrolat, chamomile hydrolat, lemon hydrolat, mint hydrolat, orange flower hydrolat and the like. They all have various efficacies and are very popular with people.
For example, the rose hydrosol is the most advocated hydrosol, wherein the Damascus rose hydrosol is obtained from a distilled stock solution within 4 hours of distilling Syria Damascus rose essential oil, the components of the stock solution are most saturated and complete, and the freshest and most nourishing hydrophilic essence of rose flower materials is perfectly reserved, so that the rose hydrosol has excellent effect and strong taste.
The rose hydrosol has fragrant and sweet smell and has the characteristics of smoothness, quietness and soothing. The rose hydrolat has strong water replenishing capacity, certain whitening effect and good anti-aging effect. In addition, it is the mildest disinfectant and astringent. Can enhance skin luster, rapidly supplement water, and enhance skin activity. Rose Bengal has mild, calming, soothing and anti-inflammatory properties, it is the mildest antiseptic and astringent, all of which make it a good skin care agent. The most sensitive skin can also be used safely with rose hydrosol, and it is also the best maintenance liquid for dry skin.
Until now, there has been no report and no commercial combination of cationic hyaluronic acid modified liposomal skin care products, particularly dermolithic liposomes incorporating three major components (ceramide, cholesterol and free fatty acids) of the intercellular lipids of the Stratum Corneum (SC), with cationic hyaluronic acid and hydrolat.
Based on the above background, in order to find a hydrolat liposome containing cationic substances and a skin-beautifying product prepared from the hydrolat liposome, the inventor takes rose hydrolat as a model hydrolat and finds that when systemic research is carried out by various technologies, the individual problems of the rose hydrolat toner, essence and the like, such as non-lasting moisturizing effect, short fragrance retention time and the like, exist respectively.
Disclosure of Invention
Through a large number of experimental researches, the inventor surprisingly discovers that the rose hydrosol skin care product prepared by adopting the specific cationic hyaluronic acid modified skin lipid-like liposome technology has a remarkable moisturizing effect, and the moisturizing time and the fragrance retaining time are remarkably prolonged. The corresponding preparation process is simple and is suitable for industrial production.
The hydrolat liposome containing the cationic hyaluronic acid can be prepared into skin care products in different forms such as toner, essence, facial mask, perfume and the like. The liposome skin care product is suitable for being prepared from various plant hydrolases including rose hydrolases, tea plant hydrolases, lavender hydrolases, jasmine hydrolases, chamomile hydrolases, lemon hydrolases, mint hydrolases, orange flower hydrolases and the like. Meets the requirements of different users on skin care products.
The invention aims to provide a hydrolat skin-imitated lipid mixed liposome containing a cationic substance and a skin-beautifying product prepared from the hydrolat skin-imitated lipid mixed liposome containing the cationic substance, wherein the skin-beautifying product can obviously prolong the moisturizing time, prolong the fragrance retention time of hydrolat and the like and is skin-friendly and smooth.
In a first aspect, the present invention provides a hydrologically pure, skin-mimicking lipid-mixed liposome containing a cationic substance, the liposome comprising: cationic substances, phospholipids, ceramides, cholesterol, free fatty acids and hydrolat; the hydrolat skin-imitated lipid mixed liposome containing cationic substances is a liposome prepared by taking 100% hydrolat as a liposome hydration medium.
The cationic substances comprise water-soluble cationic substances and fat-soluble cationic substances, and the water-soluble cationic substances are preferably selected from cationic hyaluronic acid and lauroyl arginine ethyl ester hydrochloride; the lipid-soluble cationic substance is preferably selected from the group consisting of 4- (N, N-dimethylamino) butyric acid (dilinoleyl) methyl ester (DLin-MC3-DMA), 1, 2-dioleyl-3-dimethylamino-propane (DODMA), 3 β - [ N- (N ', N' -dimethylaminoethyl) carbamoyl ] cholesterol hydrochloride (DC-CHO), (2, 3-dioleoyl-propyl) -trimethylammonium chloride (DOTAP), 1, 2-dioleoyl-sn-glycerol-3-phosphate ethanolamine (DOPE), dimethyldioctadecylammonium bromide (DDAB), or mixtures thereof.
More preferably, the cationic species is cationic hyaluronic acid, lauroyl arginine ethyl ester hydrochloride and (2, 3-dioleoyl-propyl) -trimethylammonium chloride (DOTAP) or a mixture thereof.
The phospholipid is selected from hydrogenated soybean lecithin (HSPC), soybean lecithin (SPC), egg yolk lecithin (EPC), 1, 2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1, 2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1, 2-dicaprylyl-sn-glycero-3-phosphocholine (DEPC), dimyristoyl lecithin (DMPC), 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC), 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), dimyristoyl phosphatidylethanolamine (DMPE), Distearoylphosphatidylethanolamine DSPE, dipalmitoylphosphatidylethanolamine DPPE, dioleoylphosphatidylethanolamine DOPE, dipalmitoylphosphatidylserine DPPS, Dioleoylphosphatidylserine (DOPS), dioleoylphosphatidylglycerol DOPG, egg yolk phosphatidylglycerol EPG, 1-palmitoyl-2 oleoylphosphatidylglycerol POPG-Na, 1, 2-palmitoylphosphatidylglycerol DPPG-NA, distearoylphosphatidylglycerol DSPG-Na, dimyristoylphosphatidylglycerol DMPG-Na, distearoylphosphatidic acid DSPA, dipalmitoylphosphatidic acid DPPA, preferably one or more of hydrogenated soybean lecithin (HSPC), soybean lecithin (SPC), egg yolk lecithin (EPC), 1, 2-distearoyl-sn-glycerol-3-Phosphocholine (PC), 1, 2-dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC).
The ceramide is selected from one or two of ceramide phosphorylcholine and ceramide phosphorylethanolamine.
The free fatty acid is selected from one or two of palmitic acid, linoleic acid, octadecenoic acid, linolenic acid, gamma-linolenic acid, EPA, DHA and arachidonic acid.
The hydrosol is selected from one or more of rose hydrosol, tea tree hydrosol, lavender hydrosol, sweet osmanthus hydrosol, lilac hydrosol, jasmine hydrosol, chamomile hydrosol, lemon hydrosol, mint hydrosol and orange flower hydrosol, preferably rose hydrosol.
In some embodiments of this aspect, in the hydrolat liposome containing a cationic species of the present invention, when the weight of the cationic species, phospholipid, ceramide, cholesterol, free fatty acid, and hydrolat is taken to total 100% by weight, the weight percentage of the cationic species is 0.0001% to 0.1%, preferably 0.0001% to 0.08%, more preferably 0.0005% to 0.045%, e.g., 0.0005%, 0.001%, 0.002%, 0.003%, 0.004%, 0.0045%; the weight percentage of the phospholipid is 0.2-2%, preferably 0.5-1.5%, such as 0.6%, 0.8%, 1.0%, 1.2%, 1.4%; the weight percentage of the ceramide is 0.01-2%, preferably 0.02-1%, such as 0.02%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%; the weight percentage of the cholesterol is 0.1-2%, preferably 0.1-1%, such as 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%; the weight percentage of the free fatty acid is 0.1-3%, preferably 0.1-1%, such as 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%; the balance being hydrolat.
The above-described neat dew skin lipid-mimicking mixed liposomes containing cationic species may consist of only the following components: a cationic species which is a cationic hyaluronic acid; phospholipids, which are hydrogenated soy lecithin; ceramides, which are ceramide phosphocholine; a free fatty acid which is palmitic acid; cholesterol and hydrosol, wherein the hydrosol is selected from one or more of rose hydrosol, tea tree hydrosol, lavender hydrosol, sweet osmanthus hydrosol, lilac hydrosol, jasmine hydrosol, chamomile hydrosol, lemon hydrosol, mint hydrosol and orange flower hydrosol.
The hydrologically pure skin lipid mixed liposomes containing cationic species described above may consist of only the following components: a cationic species which is lauroyl arginine ethyl ester hydrochloride; a phospholipid which is 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); a ceramide, which is ceramide phosphorylcholine; a free fatty acid which is palmitic acid; cholesterol and pure dew, wherein the pure dew is syringia oblata pure dew.
Alternatively, the above-mentioned hydrolat-like skin lipid blend liposome containing cationic substance may further contain one or more of sialic acid, Stichopus japonicus peptide, allantoin, coenzyme Q10, glycerol, vitamin A/palmitate, vitamin D, vitamin E, vitamin K, vitamin C/palmitate, palmitoyl pentapeptide-4, palmitoyl pentapeptide-3, and palmitoyl tetrapeptide.
Alternatively, the above-described neat dew skin lipid mixture liposome containing cationic substances may further contain a pH regulator and an antioxidant. The pH regulator can be one or more selected from citric acid, citrate (such as sodium citrate), maleic acid, tartaric acid, hydrochloric acid, sodium hydroxide, acetic acid, acetate (such as sodium acetate), phosphoric acid, and phosphate (such as sodium monohydrogen phosphate, sodium dihydrogen phosphate, or sodium phosphate). The antioxidant may be one or more selected from alpha-tocopherol succinate (α -tocopherol succinate), Butylated Hydroxyanisole (BHA), and Butylated Hydroxytoluene (BHT).
In a second aspect, the present invention provides a method for preparing the liposome mixture of the skin-mimicking pure dew lipid containing cationic substances, wherein the method for preparing the liposome comprises: dissolving phospholipid, ceramide, cholesterol and free fatty acid in ethanol, heating to dissolve completely, wherein the heating temperature can be 40-80 ℃, the heating mode can be water bath or air bath to obtain lipid phase, and the water bath or air bath is kept warm for later use; heating the hydrolat to 40-80 deg.c in water bath or air bath to obtain water phase; if fat-soluble cationic substances are used, preparing the lipid phase together with phospholipid, ceramide, cholesterol and free fatty acid, and if water-soluble cationic substances are used, preparing the aqueous phase together with hydrolat; mixing the obtained lipid phase and the water phase under the condition of heat preservation at 40-80 ℃ to obtain a hydrolat liposome suspension, homogenizing or extruding and granulating the obtained suspension, wherein the homogenizing pressure can be 200-2000 Bar when the homogenizing mode is selected, and the pore diameter of an extrusion film can be 50-500 nm when the extruding mode is selected, filtering, subpackaging and sealing to obtain the liposome suspension.
Preferably, the preparation method of the hydrologic mimic skin lipid mixed liposome containing the cationic substance comprises the following steps: dissolving phospholipid, ceramide, cholesterol and free fatty acid in ethanol, heating to dissolve completely to obtain lipid phase, and keeping the temperature for use; heating the hydrolat to obtain a water phase for later use; if fat-soluble cationic substances are used, preparing the lipid phase together with phospholipid, ceramide, cholesterol and free fatty acid, and if water-soluble cationic substances are used, preparing the aqueous phase together with hydrolat; mixing the obtained lipid phase and water phase to obtain hydrolat liposome suspension, granulating the obtained suspension by extrusion, filtering, packaging, and sealing.
In a third aspect, the present invention provides the use of the above-described neat dew skin-mimicking lipid mixed liposome containing a cationic substance in a skin care product. The skin-care product comprises the categories of toner, essence, mask, perfume and the like, and has the advantages of remarkable moisturizing effect and remarkably prolonged moisturizing time and fragrance retention time. The corresponding preparation process is simple and is suitable for industrial production.
Through research on the basic characteristics of the hydrosol, the inventor finds that the hydrosol, such as rose hydrosol, can be prepared into hydrosol liposome containing cationic substances by adopting specific cationic substances, specific types of phospholipids and cholesterol, and further can be prepared into skin-beautifying products, such as toner, essence, facial masks, perfume and the like, wherein the skin-beautifying products have remarkable moisturizing effect and remarkably prolonged moisturizing time and fragrance retention time.
The hydrolat skin-imitated lipid mixed liposome containing the cationic substance has good physical and chemical stability. After 12 months of standing at room temperature, the liposomes were always homogeneous liposome solutions and no demixing occurred. For example, the chemical stability of the liposome prepared in example 4 of the present invention was examined at 25 ± 2 °, and the results show that the rose hydrosol type in the liposome is not changed significantly after being placed at 25 ± 2 ℃ for 12 months, which meets the requirements of the quality control standard of cosmetics.
The inventor adds chitosan with different molecular weights into the pure dew skin-imitated lipid mixed liposome containing cationic substances, and experimental results show that after the chitosan with different molecular weights is added into the liposome, the stability of the liposome is deteriorated, specifically, the particle size is increased, layering and the like are shown, in addition, the hand feeling is poor when the liposome is smeared, the system is not uniform, and the formability is poor.
Embodiment 1. a hydrolat skin-mimicking lipid-mixed liposome containing a cationic substance, wherein the liposome comprises a cationic substance, a phospholipid, a ceramide, cholesterol, a free fatty acid, and a hydrolat.
Embodiment 2. the neat dew skin-mimicking lipid mixed liposome containing a cationic substance according to embodiment 1, wherein the cationic substance is selected from a lipid-soluble cationic substance or a water-soluble cationic substance, such as one, two or more selected from cationic hyaluronic acid, lauroyl arginine ethyl ester hydrochloride, 3 β - [ N- (N ', N' -dimethylaminoethyl) carbamoyl ] cholesterol hydrochloride (DC-CHO), (2, 3-dioleoyl-propyl) -trimethylammonium chloride (DOTAP), preferably one or two selected from cationic hyaluronic acid, lauroyl arginine ethyl ester hydrochloride and (2, 3-dioleoyl-propyl) -trimethylammonium chloride (DOTAP).
Embodiment 3. the homozygote skin lipid-mimicking mixed liposome containing a cationic substance according to any one of embodiments 1-2, wherein the phospholipid is selected from one, two or more of hydrogenated soybean lecithin (HSPC), soybean lecithin (SPC), egg yolk lecithin (EPC), 1, 2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC), 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), preferably one, two or more of hydrogenated soybean lecithin (HSPC), soybean lecithin (SPC), egg yolk lecithin (EPC), 1, 2-distearoyl-sn-glycero-3-phosphocholine (DPPC), Two or more.
Embodiment 4. the hydrolat-like skin lipid mixed liposome containing a cationic substance according to any one of embodiments 1 to 3, wherein the hydrolat is one, two or more selected from the group consisting of rose hydrolat, tea hydrolat, lavender hydrolat, osmanthus hydrolat, lilac hydrolat, jasmine hydrolat, chamomile hydrolat, lemon hydrolat, mint hydrolat and orange hydrolat, preferably rose hydrolat.
Embodiment 5. the neat dew skin lipid blend liposomes containing a cationic species according to any one of embodiments 1 to 4, wherein the ceramide is selected from one or both of ceramide phosphorylcholine and ceramide phosphorylethanolamine.
Embodiment 6. the hydrolized skin lipid blend liposome containing a cationic species according to any one of embodiments 1 to 5, wherein the free fatty acid is selected from one or more of palmitic acid, linoleic acid, octadecenoic acid, linolenic acid, gamma-linolenic acid, EPA, DHA, arachidonic acid.
Embodiment 7. a skin lipid blend liposome of a hydrolat containing a cationic species according to any one of embodiments 1 to 6, wherein the weight percentage of the cationic species is 0.0001% to 0.1%, preferably 0.0001% to 0.08%, more preferably 0.0005% to 0.045%, for example 0.0005%, 0.001%, 0.002%, 0.003%, 0.004%, 0.0045%, when the weight of the cationic species, phospholipids, ceramide, cholesterol, free fatty acids and hydrolat is taken to total 100% by weight; the weight percentage of the phospholipid is 0.2-2%, preferably 0.5-1.5%, such as 0.6%, 0.8%, 1.0%, 1.2% and 1.4%; the weight percentage of the ceramide is 0.01 to 2 percent, preferably 0.02 to 1 percent, such as 0.02 percent, 0.05 percent, 0.1 percent, 0.2 percent, 0.3 percent, 0.4 percent, 0.5 percent, 0.6 percent, 0.7 percent, 0.8 percent, 0.9 percent and 1.0 percent; the weight percentage of the cholesterol is 0.1-2%, preferably 0.1-1%, such as 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%; the weight percentage of the free fatty acid is 0.1-3%, preferably 0.1-1%, such as 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%; the balance being hydrolat.
Embodiment 8. the hydrologic mimic skin lipid mixed liposome containing a cationic species according to any of embodiments 1 to 7, wherein said cationic species is cationic hyaluronic acid; the phospholipid is hydrogenated soy lecithin (HSPC); the ceramide is ceramide phosphorylcholine; the free fatty acid is palmitic acid; the hydrolat is rose hydrolat and when the weight of cationic hyaluronic acid, hydrogenated soy lecithin (HSPC), ceramide phosphocholine, palmitic acid, cholesterol and rose hydrolat is summed up to 100 wt%, the weight percentage of cationic hyaluronic acid is 0.01%, the weight percentage of hydrogenated soy lecithin (HSPC) is 1%, the weight percentage of ceramide phosphocholine is 0.2%, the weight percentage of cholesterol is 0.3%, the weight percentage of palmitic acid is 0.4% and the weight percentage of rose hydrolat 98.09%.
Embodiment 9. the hydrologic mimic skin lipid mixed liposome containing a cationic species according to any of embodiments 1 to 7, wherein said cationic species is cationic hyaluronic acid; the phospholipid is egg yolk lecithin (EPC); the ceramide is ceramide phosphorylcholine; the free fatty acid is palmitic acid; the hydrolat is syringy hydrolat, and when the total weight of the cationic hyaluronic acid, the egg yolk lecithin (EPC), the ceramide phosphorylcholine, the palmitic acid, the cholesterol and the syringy hydrolat is 100 wt%, the weight percentage of the cationic hyaluronic acid is 0.001%, the weight percentage of the egg yolk lecithin (EPC) is 5%, the weight percentage of the ceramide phosphorylcholine is 0.5%, the weight percentage of the cholesterol is 1%, the weight percentage of the palmitic acid is 0.4%, and the weight percentage of the syringy hydrolat is 93.099%.
Embodiment 10. a hydrologic mimic skin lipid mixed liposome containing a cationic substance according to any of embodiments 1 to 7, wherein said cationic substance is lauroyl arginine ethyl ester hydrochloride; the phospholipid is 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); the ceramide is ceramide phosphoethanolamine; the free fatty acid is palmitic acid; the hydrolat is syringy pure water, and when the total weight of lauroyl arginine ethyl ester hydrochloride, 1, 2-dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC), ceramide phosphoethanolamine, palmitic acid, cholesterol and syringy pure water is 100 wt%, the weight percentage of lauroyl arginine ethyl ester hydrochloride is 0.005%, the weight percentage of 1, 2-dipalmitoyl-sn-glycerol-3-phosphocholine (DPPC) is 1.5%, the weight percentage of ceramide phosphoethanolamine is 0.5%, the weight percentage of cholesterol is 0.5%, the weight percentage of palmitic acid is 0.4%, and the weight percentage of syringy pure water is 97.095%.
Embodiment 11. a hydrolat-like skin lipid mixed liposome containing a cationic species according to any one of embodiments 1 to 7, wherein the cationic species is (2, 3-dioleoyl-propyl) -trimethylammonium chloride (DOTAP); the phospholipid is a mixture of hydrogenated soy lecithin (HSPC) and 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC); the ceramide is ceramide phosphoethanolamine; the free fatty acid is palmitic acid; the hydrolat is rose hydrosol and when the total of the weight of (2, 3-dioleoyl-propyl) -trimethylammonium chloride (DOTAP), hydrogenated soybean lecithin (HSPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), ceramide phosphoethanolamine, palmitic acid, cholesterol and rose hydrosol is 100 wt%, (0.1% by weight of 2, 3-dioleoyl-propyl) -trimethylammonium chloride (DOTAP), 1% by weight of hydrogenated soybean lecithin (HSPC), 1% by weight of 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1% by weight of ceramide phosphoethanolamine, 0.8% by weight of cholesterol, the weight percentage of the palmitic acid is 1 percent, and the weight percentage of the rose hydrosol is 95.1 percent.
Embodiment 12. a hydrologic mimic skin lipid mixed liposome containing a cationic species according to any of embodiments 1 to 7, wherein said cationic species is cationic hyaluronic acid; the phospholipid is egg yolk lecithin (EPC); the ceramide is ceramide phosphoethanolamine; the free fatty acid is palmitic acid; the hydrosol is rose hydrosol, and when the total weight of cationic hyaluronic acid, yolk lecithin (EPC), ceramide phosphoethanolamine, palmitic acid, cholesterol and rose hydrosol is 100 wt%, the weight percentage of the cationic hyaluronic acid is 0.004%, the weight percentage of the yolk lecithin (EPC) is 5%, the weight percentage of the ceramide phosphoethanolamine is 1%, the weight percentage of the cholesterol is 3%, the weight percentage of the palmitic acid is 1%, and the weight percentage of the rose hydrosol is 89.996%.
Embodiment 13 use of the hydrolized skin lipid blend liposome containing a cationic species of any one of embodiments 1 to 12 in the preparation of a skin cosmetic.
Embodiment 14. the liposome according to any one of embodiments 1 to 12, which has an average particle size of between 20nm and 4000nm, preferably between 20nm and 1000nm, more preferably between 20nm and 500nm, further preferably between 20nm and 300 nm; the Particle size distribution coefficient (PDI) of the liposome is between 0 and 0.7, preferably between 0.0001 and 0.3, more preferably between 0.001 and 0.1, and further preferably between 0.001 and 0.05; the Zeta potential of the liposome is 1 to +60mv, preferably 5 to +50mv, more preferably 10 to +40mv, and still more preferably 20 to +35 mv.
Embodiment 15. a method of preparing a hydrologically imitated skin lipid mixed liposome containing a cationic species as described in any of embodiments 1 to 12, said method comprising the steps of: dissolving phospholipid, ceramide, cholesterol and free fatty acid in ethanol, heating to dissolve completely to obtain lipid phase, and keeping the temperature for use; heating the hydrolat to obtain a water phase for later use; if fat-soluble cationic substances are used, preparing the lipid phase together with phospholipid, ceramide, cholesterol and free fatty acid, and if water-soluble cationic substances are used, preparing the aqueous phase together with hydrolat; mixing the obtained lipid phase and water phase to obtain hydrolat liposome suspension, homogenizing or extruding the suspension, filtering, packaging, and sealing.
Embodiment 16. a skin cosmetic comprising the neat skin lipid blend liposomes containing cationic species of any one of embodiments 1 to 12. The skin-beautifying product comprises toner, essence, mask, perfume and the like.
Definition of
In the context of the present application, the terms "neat dew skin lipid-mimicking mixed liposomes containing cationic species", "liposomes of the invention", "neat dew liposomes of the invention" and the like are used interchangeably and refer to liposomes prepared from cationic species, phospholipids, cholesterol and neat dew, unless the context indicates otherwise.
The term "consisting of … …" as used herein means that no significant amount of other materials is included, other than the listed components, only the presence of impurities is permitted.
The term "cationic hyaluronic acid" as used herein is a new product developed further on the basis of ordinary sodium hyaluronate, and can be adsorbed to skin and hair surface with negative charge to form a hyaluronic acid film due to positive charge. The cationic hyaluronic acid is commercially available, for example, from avavitous (shanghai) pharmaceutical technology ltd, shandong proliga biotechnology ltd, and the like.
The term "(2, 3-dioleoyl-propyl) -trimethylammonium chloride (DOTAP)" as used herein is commercially available, for example, from everavit (shanghai) pharmaceutical technology limited, Lipoid, germany, and the like.
The term "hydrogenated soybean lecithin (HSPC)" as used herein is commercially available, for example, from avigation medical science co.
The term "1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC)" as used herein is commercially available, for example, from avigation (shanghai) pharmaceutical technology limited, Lipoid, germany, and the like.
The term "lauroyl arginine ethyl ester hydrochloride" as used herein is commercially available, for example, from Shaanxi Guanchen Biotech, Inc.
The term "cholesterol" as used herein refers to cholesterol, a derivative of cyclopentanoperhydrophenanthrene. Has a chemical formula of C27H46And O. Is white or light yellow crystal, is a main steroid compound in mammals and plays an important role in basic cell life activities. Cholesterol is commercially available, for example from the family Aivianto (Shanghai) pharmaceuticalAvailable commercially from technical Co., Ltd, Lipoid in Germany, and the like.
The term "hydrolat" as used herein means a condensed aqueous solution obtained by distilling aromatic plants and flowers, which may be either self-made or commercially available. The hydrolat includes, but is not limited to, rose hydrolat, tea hydrolat, lavender hydrolat, sweet osmanthus hydrolat, lilac hydrolat, jasmine hydrolat, chamomile hydrolat, lemon hydrolat, mint hydrolat, and orange blossom hydrolat.
The terms "about," "approximately," "left-right," as used herein, mean that the numerical values given thereafter can be expanded by up to 20%. For example, "about 100" means 80% to 120%.
Detailed Description
The following examples are intended to illustrate the invention, but in no way limit the scope thereof as defined by the appended claims.
Unless otherwise stated, particle size and polydispersity index (PDI) were measured using a laser particle sizer (us PSS, model nicomz 3000), pH was measured using a pH meter (PB-10, sartorius), high performance liquid chromatography was measured using agilent 1290, the temperature units given are degrees celsius, and temperature operations not stated were performed at ambient temperature.
The meanings of abbreviations used in the examples are shown in Table 1.
TABLE 1 abbreviations
Example 1: preparation and moisturizing performance test of rose hydrosol cationic liposome
1. Prescription 1-5, screening of dosage of cationic hyaluronic acid
TABLE 2 formulation of Rose hydrosol liposomes with different amounts of cationic hyaluronic acid
The process comprises the following steps:
(1) dissolving DPPC, CH, ceramide phosphoethanolamine and palmitic acid in ethanol, and heating at 60 ℃ to completely dissolve the DPPC, CH, ceramide phosphoethanolamine and palmitic acid to obtain a lipid phase for later use;
(2) heating rose hydrosol to 60 ℃, adding HA and HAP with the prescribed amount into the rose hydrosol, and magnetically stirring until the HA and HAP are completely dissolved to obtain a water phase for later use;
(3) mixing the obtained lipid phase and water phase at 60 deg.C to obtain rose hydrosol liposome suspension, extruding the suspension with 100nm +80nm polycarbonate membrane (Woltmann Nuclepore polycarbonate membrane) for 5 times, filtering with 0.22 μm filter membrane, packaging, and sealing.
The rose hydrosol liposome added with different dosage of cationic hyaluronic acid obtained by the formulas 1-5 is a suspension with light blue opalescence. The different liposomes were characterized separately and their mean particle size, particle size distribution and Zeta potential were determined and the results are shown in table 3.
TABLE 3 characterization of Rose hydrosol liposomes with different amounts of cationic hyaluronic acid addition
"MD" means the average particle Diameter (Mean Diameter) in nm; "PDI" represents the particle size dispersion index (Polydispersity index).
Testing the moisturizing capability of the rose hydrosol liposome added with different amounts of cationic hyaluronic acid:
the test purpose is as follows: the moisturizing efficacy evaluation is carried out on the rose hydrosol liposome added with different dosage of cationic hyaluronic acid, and the moisturizing efficacy of the rose hydrosol liposome on the skin within 0h, 1h, 4h, 8h and 12h is tested, wherein the larger the skin moisture content value is, the more the skin moisture content is.
The test method comprises the following steps: according to the method of QB/T4256-2011 "guideline for evaluating moisturizing efficacy of cosmetics", a moisturizing test was performed on the rose hydrosol liposomes (corresponding to the formula 1-5, the dosage of the cationic hyaluronic acid is 0, 0.0001%, 0.001%, 0.01%, 0.1%, respectively) added with different dosages of the cationic hyaluronic acid in example 1 of the present application, and the moisturizing effect of the rose hydrosol liposomes added with different dosages of the cationic hyaluronic acid was evaluated, wherein the formula 1 is a comparative example containing no cationic hyaluronic acid.
Grouping: 50 volunteers 18-30 years old are selected and divided into 5 groups, and each prescription corresponds to 10 volunteers.
Testing indexes are as follows: skin moisture content, unit%;
the instrument comprises the following steps: ARAM HUVIS SKIN WIAZRD ASW-100 SKIN tester;
testing parts: testing the inner side of the forearm of each volunteer, and testing each volunteer 3 times each time, and taking an average value;
the results are detailed in Table 4.
TABLE 4 test results of moisturizing ability of rose hydrosol liposome added with different amounts of cationic hyaluronic acid
As can be seen from the test results in table 4, the moisturizing ability of the rose hydrosol liposome (formula 1, without cationic hyaluronic acid) prepared by using common hyaluronic acid (0.1%) reaches the maximum value within 1 hour, and then decreases sequentially with the passage of time, and returns to the level of 0 hour within 12 hours; the rose hydrosol liposome (prescription 2-5) containing different amounts of cationic hyaluronic acid is added, the dosage of the cationic hyaluronic acid in the prescription is 0.0001-0.1%, but the moisturizing capability of the rose hydrosol liposome is kept in a high moisturizing state with the lapse of time, and the rose hydrosol liposome is still high in moisturizing after 12 hours and does not fall down.
Example 2: screening of cationic substances in rose hydrosol cationic liposome
The inventor researches the cationic substance in the rose hydrosol cationic liposome, and the specific experimental design is as follows:
TABLE 5 formulations containing different cationic species
The process comprises the following steps:
(1) dissolving HSP, CH, ceramide phosphoethanolamine, palmitic acid and liposoluble cation substances (DLin-MC3-DMA, DODMA, DC-CHO, DOTAP, DOPE or DDAB) in ethanol, and heating at 60 deg.C to completely dissolve to obtain lipid phase;
(2) heating rose hydrosol to 60 deg.C, adding water soluble cationic substance (HAP or lauroyl arginine ethyl ester hydrochloride) in prescribed amount, and magnetically stirring to dissolve completely to obtain water phase;
(3) mixing the obtained lipid phase and water phase at 60 deg.C to obtain rose hydrosol liposome suspension, extruding the suspension with 100nm +80nm polycarbonate membrane for 5 times, filtering with 0.22um filter membrane, packaging, and sealing.
The rose hydrosol liposome added with different cationic substances obtained by the formulas 6-13 is a suspension with light blue opalescence. The different liposomes were characterized separately and their mean particle size, particle size distribution and Zeta potential were determined and the results are shown in table 6.
TABLE 6 characterization of Rose hydrosol liposomes for different cationic additions
"MD" means the average particle Diameter (Mean Diameter) in nm; "PDI" represents the particle size dispersion index (Polydispersity index).
Testing of moisturizing ability of rose hydrosol liposome with different cationic substance addition:
the test purpose is as follows: the moisturizing efficacy evaluation is carried out on the rose hydrosol liposome added with different cationic substances, and the moisturizing efficacy of the rose hydrosol liposome on the skin within 0h, 1h, 4h, 8h and 12h is tested, wherein the larger the skin moisture content value is, the more the skin moisture content is.
The test method comprises the following steps: according to the method of QB/T4256-2011 'guidelines for evaluating moisturizing efficacy of cosmetics', moisturizing tests are performed on the rose hydrosol liposomes (corresponding to prescriptions 6-13) added with different cationic substances in the embodiment 2 of the application, and the moisturizing effect of the rose hydrosol liposomes added with different cationic substances is evaluated.
Grouping: 80 volunteers 18-30 years old are selected and divided into 8 groups, and each prescription corresponds to 10 volunteers.
Testing indexes are as follows: skin moisture content, unit%;
the instrument comprises the following steps: ARAM HUVIS SKIN WIAZRD ASW-100 SKIN tester;
testing part: testing the inner side of the forearm of each volunteer, and testing each volunteer 3 times each time, and taking an average value;
the results are detailed in Table 7.
TABLE 7 results of testing moisturizing ability of different cationic substance-added rose hydrosol liposomes
From the test results in table 7, it is clear that the moisturizing ability of the rose hydrosol liposomes (formula 6 to formula 13) added with different cationic substances is kept in a high moisturizing state over time, and the moisturizing ability is kept high until 12 hours, and no trend is seen.
Example 3: screening of phospholipid in rose hydrosol cationic liposome
The inventor researches the phospholipid types in the rose hydrosol cationic liposome, and the specific experimental design is as follows:
TABLE 8 formulations containing different phospholipids
The process comprises the following steps:
(1) dissolving phospholipid, CH, ceramide phosphoethanolamine and palmitic acid in ethanol, and heating at 60 deg.C to completely dissolve to obtain lipid phase;
(2) heating rose hydrosol to 60 ℃, adding HAP in a prescription amount into the rose hydrosol, and magnetically stirring until the HAP is completely dissolved to obtain a water phase for later use;
(3) mixing the obtained lipid phase and water phase at 60 deg.C to obtain rose hydrosol liposome suspension, extruding the suspension with 100nm +80nm polycarbonate membrane for 5 times, filtering with 0.22um filter membrane, packaging, and sealing.
The rose hydrosol liposome prepared by the formulas 14-21 and added with different dosage of cationic hyaluronic acid is a suspension with light blue opalescence. The liposomes were characterized and the mean particle size, particle size distribution and Zeta potential were determined as shown in Table 9.
TABLE 9 characterization of Rose hydrosol liposomes with different amounts of cationic hyaluronic acid addition
"MD" means the average particle Diameter (Mean Diameter) in nm; "PDI" represents the particle size dispersion index (Polydispersity index).
Example 4: preparation of different kinds of hydrolat cationic liposome
The inventor researches the type of the hydrolat in the hydrolat cationic liposome, and the specific experimental design is as follows:
TABLE 10 formulation of cationic hydrolat liposomes containing different hydrolases
The process comprises the following steps:
(1) dissolving DPPC, CH, ceramide phosphatidyl choline and palmitic acid in ethanol, heating at 60 deg.C to completely dissolve to obtain lipid phase;
(2) heating the hydrolat to 60 ℃, adding HAP in a prescription amount into the hydrolat, and magnetically stirring the mixture until the HAP is completely dissolved to obtain a water phase for later use;
(3) mixing the obtained lipid phase and water phase at 60 deg.C to obtain hydrolat liposome suspension, extruding the suspension with 100nm +80nm polycarbonate membrane for 5 times, filtering with 0.22um filter membrane, packaging, and sealing.
The cationic liposomes corresponding to the different hydrolates obtained from formulas 22-30 are all suspensions with light blue opalescence. The liposomes were characterized and the mean particle size, particle size distribution and Zeta potential were determined as shown in Table 11.
TABLE 11 characterization of different hydrolat liposomes
"MD" means the average particle Diameter (Mean Diameter) in nm; "PDI" represents the particle size dispersion index (Polydispersity index).
Example 5: hydrosol liposome skin-beautifying product containing cationic substance
Skin-beautifying product 1 rose hydrosol liposome essence
Prescription:
| components | Weight percent | Amount of the composition |
| DPPC | 2％ | 2g |
| CH | 0.5％ | 0.5g |
| Ceramide phosphatidylcholine | 1％ | 1g |
| Palmitic acid | 2％ | 2g |
| Ethanol | 8％ | 8g |
| HAP | 0.001％ | 0.001g |
| Vitamin C | 0.01％ | 0.01 |
| Rose pure dew | Adding to 100 percent | To 100g |
| In total | 100％ | 100g |
The process comprises the following steps:
(1) dissolving DPPC, CH, ceramide phosphatidyl choline and palmitic acid in ethanol, heating at 60 deg.C to completely dissolve to obtain lipid phase;
(2) heating rose hydrosol to 60 ℃, adding HAP and vitamin C in the prescribed amount, and magnetically stirring until the HAP and the vitamin C are completely dissolved to obtain a water phase for later use;
(3) mixing the obtained lipid phase and water phase at 60 deg.C to obtain rose hydrosol liposome suspension, extruding the suspension with 400nm polycarbonate membrane for 3 times, filtering with 0.45 μm filter membrane, packaging, and sealing.
And (3) characterization of rose hydrosol liposome moisturizing essence:
the average particle size, particle size distribution, Zeta potential and water replenishing effect were measured.
| Index (I) | 0h |
| Appearance of the product | Suspension with bluish opalescence |
| Average particle diameter (n)m) | 336.65 |
| PDI | 0.03 |
| Zeta potential (mV) | 31.6 |
Water supplement test the same as example 1
Skin-beautifying product 2 rose hydrosol liposome perfume
Prescription:
| components | Weight percent | Amount of the composition |
| HSPC | 1％ | 1g |
| CH | 0.28％ | 0.28g |
| Ceramide phosphoethanolamine | 0.5％ | 0.5g |
| Linolenic acid | 1％ | 1g |
| Ethanol | 5％ | 5g |
| HAP | 0.01％ | 0.01g |
| Rose pure dew | Adding to 100 percent | To 100g |
| In total | 100％ | 100g |
The process comprises the following steps:
(1) dissolving HSPC, CH, ceramide phosphoethanolamine and linolenic acid in ethanol, and heating at 60 deg.C to completely dissolve to obtain lipid phase;
(2) heating rose hydrosol to 60 ℃, adding HAP in a prescription amount into the rose hydrosol, and magnetically stirring the mixture until the HAP is completely dissolved to obtain a water phase for later use;
(3) mixing the obtained lipid phase and water phase at 60 deg.C to obtain rose hydrosol liposome suspension, extruding the suspension with 200nm polycarbonate membrane for 5 times, filtering with 0.22um filter membrane, packaging, and sealing.
Characterization of the rose hydrosol liposome perfume:
the average particle size, the particle size distribution, the Zeta potential and the fragrance retention time of the cationic liposome perfume are measured.
| Index (I) | 0h |
| Appearance of the product | Suspension with bluish opalescence |
| Average particle diameter (nm) | 214.65 |
| PDI | 0.03 |
| Zeta potential (mV) | 29.8 |
| Fragrance time (h) | 24～28 |
Skin-beautifying product 3 lilac hydrolat liposome perfume
Prescription:
| components | Weight percent | Amount of the composition |
| SPC | 0.5％ | 0.5g |
| CH | 0.15％ | 0.15g |
| Ceramide phosphoethanolamine | 0.5％ | 0.5g |
| EPA | 1％ | 1g |
| Ethanol | 6％ | 6g |
| Lauroyl arginine ethyl ester hydrochloride | 0.01％ | 0.01g |
| Vitamin A | 0.01％ | 0.01 |
| Lilac hydrolat | Adding to 100 percent | To 100g |
| In total | 100％ | 100g |
The process comprises the following steps:
(1) dissolving HSPC, vitamin A, CH, ceramide phosphoethanolamine and EPA in ethanol, and heating at 60 deg.C to dissolve completely to obtain lipid phase;
(2) heating syringa vulgaris hydrolat to 60 ℃, adding lauroyl arginine ethyl ester hydrochloride with a prescription amount into the syringa vulgaris hydrolat, and magnetically stirring the mixture until the lauroyl arginine ethyl ester hydrochloride is completely dissolved to obtain a water phase for later use;
(3) mixing the obtained lipid phase and water phase at 60 deg.C to obtain syringyl flos pure dew liposome suspension, extruding the suspension with 200nm polycarbonate membrane for 5 times, filtering with 0.22um filter membrane, packaging in perfume bottle, and sealing.
Characterization of syringa oblata liposome perfume:
the average particle size, the particle size distribution, the Zeta potential and the fragrance retention time of the cationic liposome perfume are measured.
Skin-beautifying product 4-osmanthus hydrolat liposome moisturizing essence
Prescription:
| components | Weight percent | Dosage of |
| POPC | 1.5％ | 1.5g |
| CH | 0.5％ | 0.5g |
| Ceramide phosphoethanolamine | 0.1％ | 0.1g |
| Palmitic acid | 2％ | 2g |
| Ethanol | 6％ | 6g |
| HAP | 0.001％ | 0.001g |
| Osmanthus flower hydrolat | Adding to 100 percent | To 100g |
| In total | 100％ | 100g |
The process comprises the following steps:
(1) dissolving POPC, CH, ceramide phosphoethanolamine and palmitic acid in ethanol, and heating at 60 deg.C to completely dissolve to obtain lipid phase;
(2) heating the osmanthus hydrolat to 60 ℃, adding HAP in a prescription amount into the osmanthus hydrolat, and magnetically stirring until the HAP is completely dissolved to obtain a water phase for later use;
(3) mixing the obtained lipid phase and water phase at 60 deg.C to obtain Osmanthus fragrans hydrolat liposome suspension, extruding the suspension with 200nm polycarbonate membrane for 3 times, filtering with 0.22um filter membrane, packaging, and sealing.
Characterization of water supplement essence of osmanthus hydrolat liposome:
the average particle size, particle size distribution, Zeta potential and water replenishing effect were measured.
| Index (I) | 0h |
| Appearance of the product | Suspension with bluish opalescence |
| Average particle diameter (nm) | 198.56 |
| PDI | 0.03 |
| Zeta potential (mV) | 31.7 |
Water supplement test the same as example 1
Skin-beautifying product 5 orange flower hydrolat liposome perfume
Prescription:
| components | Weight percent | Dosage of |
| HSPC | 1％ | 1g |
| CH | 0.28％ | 0.28g |
| Ceramide phosphatidylcholine | 1％ | 1g |
| Octadecenoic acid | 2％ | 2g |
| Ethanol | 8％ | 8g |
| DOTAP | 0.01％ | 0.01g |
| Citric acid | 0.1％ | 0.1 |
| Orange flower hydrosol | Adding to 100 percent | To 100g |
| In total | 100％ | 100g |
The process comprises the following steps:
(1) dissolving HSPC, CH, ceramide phosphatidyl choline and octadecenoic acid in ethanol, and heating at 60 deg.C to completely dissolve to obtain lipid phase;
(2) heating the orange flower hydrolat to 60 ℃, adding HAP and citric acid in a prescription amount into the orange flower hydrolat, and magnetically stirring until the HAP and the citric acid are completely dissolved to obtain a water phase for later use;
(3) mixing the obtained lipid phase and water phase at 60 deg.C to obtain neroli hydrolat liposome suspension, extruding the suspension with 100nm +80nm polycarbonate membrane for 5 times, filtering with 0.22um filter membrane, packaging, and sealing.
Orange flower hydrolat liposome perfume characterization:
the average particle size, the particle size distribution, the Zeta potential and the fragrance retention time of the cationic liposome perfume are measured.
| Index (I) | 0h |
| Appearance of the product | Suspension with bluish opalescence |
| Average particle diameter (nm) | 92.43 |
| PDI | 0.04 |
| Zeta potential (mV) | 28.8 |
| Fragrance time (h) | 24～28 |
Skin-beautifying 6 jasmine flower hydrolat liposome perfume
Prescription:
the process comprises the following steps:
(1) dissolving HSPC, CH, ceramide phosphatidylcholine and linoleic acid in ethanol, and heating at 60 deg.C to completely dissolve to obtain lipid phase;
(2) heating jasmine hydrolat to 60 ℃, adding lauroyl arginine ethyl ester hydrochloride with the formula amount into the jasmine hydrolat, and magnetically stirring the mixture until the lauroyl arginine ethyl ester hydrochloride is completely dissolved to obtain a water phase for later use;
(3) mixing the obtained lipid phase and water phase at 60 deg.C to obtain flos Jasmini sambac hydrolat liposome suspension, extruding the suspension with 100nm polycarbonate membrane for 5 times, filtering with 0.22um filter membrane, packaging in perfume bottle, and sealing.
Characterization of the jasmine hydrolat liposome perfume:
the average particle size, the particle size distribution, the Zeta potential and the fragrance retention time of the cationic liposome perfume are measured.
| Index (I) | 0h |
| Appearance of the product | Suspension with bluish opalescence |
| Average particle diameter (nm) | 105.47 |
| PDI | 0.08 |
| Zeta potential (mV) | 29.8 |
| Fragrance time (h) | 28～48 |
All patent and non-patent documents cited herein are incorporated by reference in their entirety as if each were individually set forth in its entirety.
While specific embodiments and examples are provided herein to illustrate the invention, this is not to be construed as limiting the scope of the invention. Based on the disclosure, it will be apparent to those skilled in the art that other modifications and equivalents can be made without departing from the spirit of the invention, and these modifications and equivalents are within the scope of the invention.
Claims (10)
1. A skin lipid-like mixed liposome containing a hydrosol containing a cationic substance, which is characterized in that the liposome comprises the cationic substance, phospholipid, ceramide, cholesterol, free fatty acid and hydrosol.
2. The perhydrol skin lipid mixed liposome containing cationic substance according to claim 1, characterized in that said cationic substance is selected from one or two of fat-soluble cationic substance and water-soluble cationic substance, and is preferably selected from one, two or more of cationic hyaluronic acid, lauroyl arginine ethyl ester hydrochloride, 3 β - [ N- (N ', N' -dimethylaminoethyl) carbamoyl ] cholesterol hydrochloride (DC-CHO), (2, 3-dioleoyl-propyl) -trimethyl ammonium chloride (DOTAP), and is preferably selected from one or two of cationic hyaluronic acid, lauroyl arginine ethyl ester hydrochloride and (2, 3-dioleoyl-propyl) -trimethyl ammonium chloride (DOTAP).
3. The homoleptic dermalogue mixed liposome containing cationic substance according to claim 1 or 2, wherein said phospholipid is selected from one, two or more of hydrogenated soybean lecithin (HSPC), soybean lecithin (SPC), egg yolk lecithin (EPC), 1, 2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC), 1, 2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1, 2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), preferably one of hydrogenated soybean lecithin (HSPC), soybean lecithin (SPC), egg yolk lecithin (EPC), 1, 2-distearoyl-sn-glycero-3-phosphocholine (DPPC), a mixture of hydrogenated soybean lecithin (HSPC), soybean lecithin (EPC), 1, 2-distearoyl-sn-glycero-3-phosphocholine (DPPC), Two or more.
4. The neat skin lipid blend liposome containing cationic species of any one of claims 1 to 3, wherein the ceramide is selected from one or both of ceramide phosphorylcholine and ceramide phosphorylethanolamine.
5. The homoleptic skin lipid blend liposome containing cationic species of any of claims 1 to 4, wherein the free fatty acid is selected from one or more of palmitic acid, linoleic acid, octadecenoic acid, linolenic acid, γ -linolenic acid, EPA, DHA, arachidonic acid.
6. The hydrosol skin lipid-mixture liposome containing cationic substances according to any one of claims 1 to 5, wherein the hydrosol is selected from one or more of rose hydrosol, tea plant hydrosol, lavender hydrosol, sweet osmanthus hydrosol, lilac hydrosol, jasmine hydrosol, chamomile hydrosol, lemon hydrosol, mint hydrosol, and orange flower hydrosol, preferably rose hydrosol.
7. A hydrologic skin lipid blend liposome containing a cationic species according to anyone of claims 1 to 6, wherein the weight percentage of said cationic species is between 0.0001% and 0.1%, preferably between 0.0001% and 0.08%, more preferably between 0.0005% and 0.045%, such as 0.0005%, 0.001%, 0.002%, 0.003%, 0.004%, 0.0045% when the weight of cationic species, phospholipids, ceramide, cholesterol, free fatty acids and hydrologic are taken to total 100% by weight; the weight percentage of the phospholipid is 0.2-2%, preferably 0.5-1.5%, such as 0.6%, 0.8%, 1.0%, 1.2%, 1.4%; the weight percentage of the ceramide is 0.01-2%, preferably 0.02-1%, such as 0.02%, 0.05%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%; the weight percentage of the cholesterol is 0.1-2%, preferably 0.1-1%, such as 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%; the weight percentage of the free fatty acid is 0.1-3%, preferably 0.1-1%, such as 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%; the balance being hydrolat.
8. A method of preparing a hydrologic mimic skin lipid mixed liposome containing cationic species according to any of claims 1 to 7, said method comprising the steps of: dissolving phospholipid, ceramide, cholesterol and free fatty acid in ethanol, heating to dissolve completely to obtain lipid phase, and keeping the temperature for use; heating the hydrolat to obtain a water phase for later use; if fat-soluble cationic substances are used, preparing the lipid phase together with phospholipid, ceramide, cholesterol and free fatty acid, and if water-soluble cationic substances are used, preparing the aqueous phase together with hydrolat; mixing the obtained lipid phase and water phase to obtain hydrolat liposome suspension, homogenizing or extruding the suspension, filtering, packaging, and sealing.
9. A skin cosmetic comprising a hydrologic mimic skin lipid mixed liposome containing a cationic species according to any one of embodiments 1 to 7.
10. The skin cosmetic of claim 9, comprising a toner, a serum, a mask, a perfume.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210223465.8A CN114601766A (en) | 2022-03-07 | 2022-03-07 | A skin lipid mixed liposome containing cationic substances and skin-caring product prepared from the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210223465.8A CN114601766A (en) | 2022-03-07 | 2022-03-07 | A skin lipid mixed liposome containing cationic substances and skin-caring product prepared from the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114601766A true CN114601766A (en) | 2022-06-10 |
Family
ID=81861466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210223465.8A Pending CN114601766A (en) | 2022-03-07 | 2022-03-07 | A skin lipid mixed liposome containing cationic substances and skin-caring product prepared from the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114601766A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001042424A2 (en) * | 1999-11-29 | 2001-06-14 | The Collaborative Group, Ltd. | Sphingolipid-containing cationic liposomes for topical delivery of bioactive material |
| CN103284950A (en) * | 2012-02-28 | 2013-09-11 | 中国医科大学附属盛京医院 | Sebum liposome and preparation method for same |
| WO2017177869A1 (en) * | 2016-04-11 | 2017-10-19 | 百奥迈科生物技术有限公司 | Liposome preparation having high-content cationic lipid compound and use thereof |
| CN113518611A (en) * | 2019-09-24 | 2021-10-19 | 科丝美诗株式会社 | Multilamellar cationic liposome for enhancing skin absorption and preparation method thereof |
-
2022
- 2022-03-07 CN CN202210223465.8A patent/CN114601766A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001042424A2 (en) * | 1999-11-29 | 2001-06-14 | The Collaborative Group, Ltd. | Sphingolipid-containing cationic liposomes for topical delivery of bioactive material |
| CN103284950A (en) * | 2012-02-28 | 2013-09-11 | 中国医科大学附属盛京医院 | Sebum liposome and preparation method for same |
| WO2017177869A1 (en) * | 2016-04-11 | 2017-10-19 | 百奥迈科生物技术有限公司 | Liposome preparation having high-content cationic lipid compound and use thereof |
| CN113518611A (en) * | 2019-09-24 | 2021-10-19 | 科丝美诗株式会社 | Multilamellar cationic liposome for enhancing skin absorption and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 张根旺 等: "脂质体化妆品及其应用", 郑州工程学院学报 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7075377B2 (en) | Compositions Containing Polymer Aggregates of Lipids and Surfactants | |
| Bendas et al. | Enhanced transdermal delivery of salbutamol sulfate via ethosomes | |
| US5643600A (en) | Lipid vesicles containing avocado oil unsaponifiables | |
| JP5142989B2 (en) | Composition comprising lipid and copolymer of styrene and maleic acid | |
| DE69631970T2 (en) | Archaeoliposomes, coenzyme Q10 containing archaeoliposomes and coenzyme Q10 containing liposomes as adjuvant and drug delivery vehicle | |
| US8906397B2 (en) | Permeation enhancers for topical formulations | |
| JP6231624B2 (en) | Method for producing nanoliposomes for cosmetics in which oleanolic acid is collected | |
| JPH06502158A (en) | Hot spring water liposomes stabilized in DNA gel | |
| US10426715B2 (en) | Liposome composition | |
| KR102164218B1 (en) | Multilayer cationic liposome for enhancing the skin penetration and preparation method thereof | |
| JP2009120584A (en) | Cosmetic composition in form of emulsion comprising continuous aqueous phase and dispersed fatty phase and preparation method thereof | |
| JP5863230B2 (en) | Liposomes encapsulating oxazolidin-2-one compounds | |
| KR101176523B1 (en) | A Cosmetic Composition having phase transformation | |
| KR20210059277A (en) | Self-assembled lipid vesicle and cosmetic composition comprising same | |
| EP3381517B1 (en) | Phospholipid three-dimensional vesicular aggregates scattered in alcoholic mixtures with no or low water content, their preparation and use in formulations for topical application | |
| CN109414390B (en) | External preparation for skin | |
| CN114601766A (en) | A skin lipid mixed liposome containing cationic substances and skin-caring product prepared from the same | |
| US11826468B2 (en) | Insoluble active substance carrier comprising transfersome | |
| CA2177696C (en) | Lipid vesicles containing avocado oil unsaponifiables | |
| KR20190102753A (en) | elastic liposome composition for accelerating skin absorption, elastic liposome containing thereof and manufacturing method thereof | |
| Monisha et al. | Liposomes as targeted drug delivery system: A review. | |
| JP2002179549A (en) | Skin care preparation | |
| WO2024014664A1 (en) | Liposome composition having increased skin absorption and efficacy through enhanced adhesion, and method for preparing same | |
| KR102632236B1 (en) | Liposome complex and cosmetic composition for improving skin condition comprising the same | |
| Niesman et al. | Liposome uptake by human retinal pigment epithelial cells in culture |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |